Veracyte, Inc.
VCYT
$30.43
-$0.53-1.71%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.81% | 28.58% | 26.69% | 17.50% | 22.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.81% | 28.58% | 26.69% | 17.50% | 22.29% |
| Cost of Revenue | 26.18% | 22.90% | 13.20% | 21.61% | 9.49% |
| Gross Profit | 18.51% | 31.09% | 33.29% | 13.80% | 28.72% |
| SG&A Expenses | 3.83% | 18.87% | 8.58% | -8.14% | 16.24% |
| Depreciation & Amortization | -20.91% | -28.86% | -29.04% | -31.45% | -13.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.09% | 19.22% | 10.83% | 3.12% | 18.80% |
| Operating Income | 334.38% | 286.02% | 167.15% | 120.66% | 35.38% |
| Income Before Tax | 111.30% | 156.59% | 188.93% | 76.42% | -785.56% |
| Income Tax Expenses | 23.36% | 1,199.35% | 1,201.60% | -- | -640.69% |
| Earnings from Continuing Operations | 118.07% | 151.17% | 168.25% | 76.96% | -636.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 118.07% | 151.17% | 168.25% | 76.96% | -636.03% |
| EBIT | 334.38% | 286.02% | 167.15% | 120.66% | 35.38% |
| EBITDA | 372.60% | 72.45% | 1,034.90% | 360.70% | 117.88% |
| EPS Basic | 117.03% | 148.38% | 164.62% | 77.79% | -623.36% |
| Normalized Basic EPS | 298.61% | 214.09% | 193.28% | 163.61% | 151.61% |
| EPS Diluted | 115.84% | 146.34% | 158.33% | 77.79% | -623.36% |
| Normalized Diluted EPS | 286.81% | 208.41% | 192.58% | 163.61% | 151.61% |
| Average Basic Shares Outstanding | 6.16% | 5.78% | 5.60% | 3.58% | 1.78% |
| Average Diluted Shares Outstanding | 9.30% | 7.77% | 6.46% | 3.58% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
